ClinicalTrials.gg
TerminatedNCT02548962Updated Nov 21, 2019Results posted

Study of Ibrutinib in Combination With Pomalidomide and Dexamethasone in Subjects With Relapsed/Refractory Multiple Myeloma

A Phase 1/2 interventional study of Ibrutinib and Pomalidomide in Multiple Myeloma, sponsored by Pharmacyclics LLC.. Terminated at 16 sites in 6 countries. Open to participants aged 18 Years to 100 Years. Per ClinicalTrials.gov, last updated 2019-11-21.

Sponsored by Pharmacyclics LLC. (part of AbbVie) · Phase 1/2, Interventional, and Treatment

Why this study was terminated
After completing Phase 1, the Sponsor elected not to move forward with Phase 2.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
11
Allocation
Non-randomized
Ages
18 Years to 100 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 40 studies in Multiple Myeloma by AbbVie — 7 open to participants now, 17 under way, 5 of them phase 3. Multiple Myeloma · AbbVie.

Enrollment
31st of 39
11 · median 84
Started
2016
with 2 others
Phase 1/2
7 of 40
2 open now
Registered
14th of 40
by date

Among the 40 studies in Multiple Myeloma by AbbVie, this one is the 31st largest by enrollment of the 39 interventional ones that give a count, is one of 3 that started in 2016, is one of 7 in phase 1/2, and was the 14th registered.

Multiple Myeloma

3,763 studies on the registry are indexed under Multiple Myeloma; 770 are open to participants now.

Browse Multiple Myeloma studies →

Open to participants now

7 of the 40 studies in Multiple Myeloma by AbbVie are open now, in 12 countries. Recruiting first, the newest first:

2 more — sign in →

By country, each count listing its studies:

All 7 open studies →

Who these studies take

Of the 585 Multiple Myeloma studies recruiting now, 430 (74%) set no upper age limit and 106 (18%) stop at 75 or younger; 36 take children under 18; 24 take healthy volunteers.

This study: 18 Years to 100 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 40 studies in Multiple Myeloma by AbbVie, or all of them as a file.
02

Study summary

Phase 1 is an open-label, dose finding, multicenter study of ibrutinib in combination with pomalidomide and dexamethasone in subjects with relapsed/refractory multiple myeloma.

Phase 2b is a randomized, double-blind, multicenter study of ibrutinib or placebo, in combination with pomalidomide and dexamethasone in subjects with relapsed/refractory multiple myeloma.

Read the detailed description

Bruton's tyrosine kinase (Btk) is an enzyme that is present in hematopoietic cells other than T cells and is necessary for downstream signal transduction from various hematopoietic receptors including the B cell receptor as well as some Fc, chemokine, and adhesion receptors, and is crucial for both B cell development and osteoclastogenesis. Although down-regulated in normal plasma cells, Btk is highly expressed in the malignant cells from many myeloma patients and some cell lines. Ibrutinib is a potent and specific inhibitor of Btk currently in Phase 2 and 3 clinical trials. The current study is designed and intended to determine the safety and efficacy of ibrutinib in combination with pomalidomide and dexamethasone in subjects with relapsed/refractory multiple myeloma.

03

Conditions studied

  • Multiple Myeloma

Browse trials for

Keywords

  • Multiple Myeloma
  • Bruton's Tyrosine Kinase
  • PCI-32765
  • Pomalidomide
  • Dexamethasone
  • Relapsed Refractory Multiple Myeloma
  • Ibrutinib
04

Who can participate

Ages eligible
18 Years to 100 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subjects with MM who have received at least two including lenalidomide and either bortezomib or carfilzomib and have demonstrated disease progression on or within 60 days of the completion of the most recent treatment regimen.
  • defined by at least ONE of the following:

    1. Serum monoclonal protein (SPEP) ≥1 g/dL.
    2. Urine monoclonal protein (UPEP) ≥200 mg by 24 hour urine.
  • Adequate hematologic, hepatic, and renal function
  • performance status of ≤ 2

Exclusion criteria

Exclusion Criteria:

  • Subject must not have primary disease
  • Plasma cell leukemia, primary amyloidosis or POEMS syndrome
  • Unable to swallow capsules or disease significantly affecting gastrointestinal function
  • Requires treatment with strong inhibitors
  • Women who are pregnant or breast feeding.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
11 participants (actual)

Study arms

  • Experimental
    Phase 1: Dose Finding

    Ibrutinib PO+ Pomalidomide PO+ Dexamethasone PO

    Drug: Ibrutinib · Drug: Pomalidomide · Drug: Dexamethasone

  • Experimental
    Phase 2: Treatment Arm A

    Ibrutinib PO+ Pomalidomide PO+ Dexamethasone PO

    Drug: Ibrutinib · Drug: Pomalidomide · Drug: Dexamethasone

  • Experimental
    Phase 2: Treatment Arm B

    Placebo PO+ Pomalidomide PO+ Dexamethasone PO

    Drug: Pomalidomide · Drug: Dexamethasone · Drug: Placebo

Interventions

06

What researchers measure

Primary outcomes

  1. Overall Response Rate (ORR) According to the IMWG Response Criteria Per Investigator Assessment

    The overall response rate, defined as the proportion of subjects achieving a best overall response of PR or better per investigator assessment per IMWG at or prior to initiation of subsequent anticancer therapy

    Time frame: 14 Months

Secondary outcomes

  1. Clinical Benefit Response (CBR)

    The clinical benefit response, defined as the proportion of subjects achieving a best overall response of MR or better per investigator assessment per IMWG at or prior to initiation of subsequent anticancer therapy.

    Time frame: 14 Months

  2. Duration of Response (DOR)

    The time interval between the date of initial documentation of a response and the date of first documented evidence of progressive disease, death, or date of censoring for the subjects not progressed/died. The censoring date is the last adequate tumor assessment date.

    Time frame: 14 Months

07

Results

Posted Apr 23, 2019

Participant flow

Participant flow — Overall Study
MilestonePhase 1: Dose Finding (560mg)Phase 1: Dose Finding (840mg)
Started83
Completed73
Not completed10
Withdrew: Withdrawal by subject10

Outcome measures

PrimaryOverall Response Rate (ORR) According to the IMWG Response Criteria Per Investigator Assessment

The overall response rate, defined as the proportion of subjects achieving a best overall response of PR or better per investigator assessment per IMWG at or prior to initiation of subsequent anticancer therapy

Time frame:
14 Months
Reported as:
Count of participants · Participants
Overall Response Rate (ORR) According to the IMWG Response Criteria Per Investigator Assessment
ParticipantsPhase 1: Dose Finding (560mg)Phase 1: Dose Finding (840mg)
Overall Response Rate (ORR) According to the IMWG Response Criteria Per Investigator Assessment31
SecondaryClinical Benefit Response (CBR)

The clinical benefit response, defined as the proportion of subjects achieving a best overall response of MR or better per investigator assessment per IMWG at or prior to initiation of subsequent anticancer therapy.

Time frame:
14 Months
Reported as:
Count of participants · Participants
Clinical Benefit Response (CBR)
ParticipantsPhase 1: Dose Finding (560mg)Phase 1: Dose Finding (840mg)
Clinical Benefit Response (CBR)42
SecondaryDuration of Response (DOR)

The time interval between the date of initial documentation of a response and the date of first documented evidence of progressive disease, death, or date of censoring for the subjects not progressed/died. The censoring date is the last adequate tumor assessment date.

Time frame:
14 Months
Reported as:
Median · Months
Duration of Response (DOR)
MonthsPhase 1: Dose Finding (560 mg)Phase 1: Dose Finding (840 mg)
Duration of Response (DOR)6.5 (5.1 to 11.8)7.3 (7.3 to 7.3)

Adverse events

Collected over 14 Months. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Phase 1: Dose Finding (560mg)1/8 (12.5%)8/8 (100%)8/8 (100%)
Phase 1: Dose Finding (840mg)1/3 (33.3%)3/3 (100%)3/3 (100%)
Most frequent serious events
Showing 10 of 16
Most frequent serious events
EventPhase 1: Dose Finding (560mg)Phase 1: Dose Finding (840mg)
PneumoniaInfections and infestations1/81/3
Urinary Tract InfectionInfections and infestations1/81/3
Cardiac FailureCardiac disorders0/81/3
DehydrationMetabolism and nutrition disorders0/81/3
EmbolismVascular disorders0/81/3
Subdural HaemorrhageInjury, poisoning and procedural complications0/81/3
Atrial FibrilationCardiac disorders1/80/3
Cardio-respiratory ArrestCardiac disorders1/80/3
DiarrhoeaGastrointestinal disorders1/80/3
Febrile NeutropeniaBlood and lymphatic system disorders1/80/3
Most frequent other events
Showing 10 of 77
Most frequent other events
EventPhase 1: Dose Finding (560mg)Phase 1: Dose Finding (840mg)
AnaemiaBlood and lymphatic system disorders6/82/3
DiarrhoeaGastrointestinal disorders2/82/3
NauseaGastrointestinal disorders2/82/3
FatigueGeneral disorders5/82/3
ThrombocytopeniaBlood and lymphatic system disorders4/81/3
NeutropeniaBlood and lymphatic system disorders4/80/3
Upper Respiratory Tract InfectionInfections and infestations4/80/3
Increased Tendency to BruiseBlood and lymphatic system disorders0/81/3
Spontaneous HaematomaBlood and lymphatic system disorders0/81/3
TachycardiaCardiac disorders0/81/3

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Phase 1: Dose Finding (560mg)Phase 1: Dose Finding (840mg)Total
<=18 years000
Between 18 and 65 years505
>=65 years336
Age, Continuous
Age, Continuous(years)Phase 1: Dose Finding (560mg)Phase 1: Dose Finding (840mg)Total
Median63.5 (53 to 81)72.7 (67 to 77)67.5 (53 to 81)
Sex: Female, Male
Sex: Female, Male(Participants)Phase 1: Dose Finding (560mg)Phase 1: Dose Finding (840mg)Total
Female336
Male505
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Phase 1: Dose Finding (560mg)Phase 1: Dose Finding (840mg)Total
Hispanic or Latino112
Not Hispanic or Latino628
Unknown or Not Reported101
Region of Enrollment
Region of Enrollment(participants)Phase 1: Dose Finding (560mg)Phase 1: Dose Finding (840mg)Total
Greece303
United States303
Czechia224
Australia011
08

Study locations

16 sites
  • City of Hope
    Duarte, California 91010, United States
  • Dana-Farber Cancer Institute
    Boston, Massachusetts 02215, United States
  • Cleveland Clinic
    Cleveland, Ohio 44195, United States
  • Medical University of South Carolina
    Charleston, South Carolina 29425, United States
  • Virginia Commonwealth University
    Richmond, Virginia 23298, United States
  • Concord Repatriation General Hospital
    Concord, New South Wales 2139, Australia
  • Princess Alexandra Hospital
    Woolloongabba, Queensland 4102, Australia
  • Fakultni nemocnice Brno
    Brno, 625 00, Czechia
  • Fakultni nemocnice Ostrava
    Ostrava, 708 52, Czechia
  • Vseobecna fakultni nemocnice v Praze
    Praha, 128 08, Czechia
  • Universitätsklinikum Carl Gustav Carus
    Dresden, 01307, Germany
  • 'Alexandra' General Hospital of Athens
    Athens, Attiki 11528, Greece
  • Clinica Universidad de Navarra
    Pamplona, Navarra 31008, Spain
  • Hospital de La Santa Creu i Sant Pau
    Barcelona, 08025, Spain
  • Hospital Universitario de Salamanca
    Salamanca, 37007, Spain
  • Hospital Universitario Doctor Peset
    Valencia, 46017, Spain
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Mar 2016, a primary completion of Jun 2018 and a completion of Jun 2018. It does not say whether these dates are actual or estimated.

Results were first posted in Apr 2019, 10 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 3, 2015
First posted
Sep 14, 2015
Start
Mar 2016
Primary completionActual
Jun 13, 2018
CompletionActual
Jun 13, 2018
Results first posted
Apr 23, 2019
Last update
Nov 21, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 21, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02548962
Lead sponsor
Pharmacyclics LLC.
Collaborators
Celgene Corporation
Responsible party
Sponsor
First posted
Sep 14, 2015
Start date
Mar 2016
Primary completion
Jun 13, 2018
Completion
Jun 13, 2018
Results posted
Apr 23, 2019
Last update
Nov 21, 2019

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Nov 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ibrutinib

Start the discussion